OncoMatch/Clinical Trials/NCT06287528
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Is NCT06287528 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies 19-28z/IL-18 CAR T cells for philadelphia-negative all.
Treatment: 19-28z/IL-18 CAR T cells — Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy that participants will receive during the study. Making the participants' study therapy will take about 2-4 weeks.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positivity on leukemia blasts if prior anti-CD19 treatment
Documentation of CD19 positivity on leukemia blasts if prior anti-CD19 treatment
Performance status
ECOG/LANSKY 0–1
ECOG performance status 0-1 or Lansky performance status ≥ 60 for patients < 16 years old
Demographics
Prior therapy
Must have received: multiagent systemic chemotherapy (induction and consolidation) — relapsed/refractory Ph-negative B-ALL
Refractory or relapsed disease to at least 1 prior multiagent systemic chemotherapy regimen that included both induction and consolidation therapy
Must have received: second- or third-generation tyrosine kinase inhibitor — relapsed/refractory Ph-positive B-ALL
persistent or progressive disease following at least 1 prior second- or third-generation tyrosine kinase inhibitor
Lab requirements
Kidney function
Serum creatinine <2.0mg/100mL
Liver function
ALT or AST ≤5x ULN and total bilirubin ≤2 (or ≤3 if history of Gilbert's syndrome or leukemic infiltration of the liver)
Cardiac function
SaO2 ≥92% on room air; Left ventricular ejection fraction (LVEF) ≥50% within 1 month of screening
Adequate organ function at time of screening, including: ALT or AST ≤5x ULN and total bilirubin ≤2 (or ≤3 if history of Gilbert's syndrome or leukemic infiltration of the liver); Serum creatinine <2.0mg/100mL; SaO2 ≥92% on room air; Left ventricular ejection fraction (LVEF) ≥50% within 1 month of screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Suffolk-Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06287528 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received multiagent systemic chemotherapy (induction and consolidation) and second- or third-generation tyrosine kinase inhibitor.
Does this trial require CD19?
Yes, CD19 positivity on leukemia blasts if prior anti-CD19 treatment is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages